Bill Spreen, Pharm.D, is a Director of Research and Development in GlaxoSmithKline’s (GSK) Infectious Diseases Therapy Area and based in Research Triangle Park, North Carolina. Currently, Dr. Spreen is Medicine Development Leader for the HIV integrase inhibitor cabotegravir (GSK1256744), a long-acting injectable agent under investigation for both HIV prevention and treatment. In his 20-plus years with GSK, he has led global development programs for a number of small molecule antiretroviral agents, culminating in approval of dolutegravir, abacavir and the combination products Trizivir and Epzicom/Kivexa, Dr. Spreen and colleagues also led GSK’s efforts to validate the clinical utility of a genetic-based screening test for abacavir hypersensitivity reaction. Dr. Spreen joined GSK after receiving his Pharm.D. from The Ohio State University, Columbus, Ohio.